Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
SAN DIEGO, May 11, 2017 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced regulatory approvals in select international markets.
Obalon has received notification that it has obtained the necessary regulatory approvals in select Middle East markets to commercialize the Obalon six-month balloon and the associated inflation dispenser. Obalon intends to fulfill an initial order to its Middle East distributor, Bader Sultan, during the second quarter of 2017.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
For Obalon Therapeutics, Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 [email protected] Media: Megan Driscoll EvolveMKD Office Phone: +1 646 517 4220 [email protected]
